⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 11, 2025

Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC

Gözde Mütevelizade Nazım Aydın Atike Pınar Erdoğan Bilal Çağrı Bozdemir Nagihan Kolkıran Elvan Sayıt

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective analysis reveals metabolic markers predict survival in NSCLC patients on nivolumab, suggesting treatment optimization.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mütevelizade et al. (2025) studied this question.

synapsesocial.com/papers/68a36f8a0a429f7973332770 https://doi.org/10.71286/moi.1727407

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prognostic value of 18F-FDG PET/CT metabolic parameters in patients with non–small cell lung cancer who achieved a pathological complete response after neoadjuvant chemoimmunotherapyOriginal Research · 2026
2Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with NivolumabCohort Study · 2026 · 1 citations
3Total metabolic tumor volume on<sup>18</sup>F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy2024 · 38 citations
4Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy2025 · 2 citations
5The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer2024 · 16 citations

More related papers

Comparison of the Prognostic Value of PET Metabolic Parameters and Postoperative Pathologic Response After Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer2026
Molecular imaging research on 18F-FDG PET/CT and biomarker analysis to predict the efficacy of neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC.2024
Can <scp>FDG</scp>‐<scp>PET</scp> after neoadjuvant chemotherapy plus nivolumab predict residual disease in non‐small cell lung cancer?2024